4//SEC Filing
Klee Justin B. 4
Accession 0001193125-25-228343
CIK 0001658551other
Filed
Oct 1, 8:00 PM ET
Accepted
Oct 2, 4:15 PM ET
Size
6.9 KB
Accession
0001193125-25-228343
Insider Transaction Report
Form 4
Klee Justin B.
DirectorCo-Chief Executive Officer
Transactions
- Sale
Common Stock
2025-09-30$14.37/sh−29,775$427,950→ 3,325,501 total - Sale
Common Stock
2025-09-30$15.01/sh−200$3,002→ 3,325,301 total
Footnotes (3)
- [F1]Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.99 to $14.98. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.02. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Documents
Issuer
Amylyx Pharmaceuticals, Inc.
CIK 0001658551
Entity typeother
Related Parties
1- filerCIK 0001898314
Filing Metadata
- Form type
- 4
- Filed
- Oct 1, 8:00 PM ET
- Accepted
- Oct 2, 4:15 PM ET
- Size
- 6.9 KB